{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-055490","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2026-08-11T11:14:05+00:00","discovered_at":"2026-08-11T11:15:00.441918+00:00","generated_at":"2026-08-11T11:15:13.007304+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"C4T Q2 2026 net loss $23.6M ($0.18/sh), cash $300.4M, cemsidomide trials on track","bullets":["Q2 2026 revenue $6.6M (vs $6.5M YoY); net loss $23.6M vs $26.0M; EPS -$0.18 vs -$0.37.","Cash, equivalents & securities $300.4M at Jun 30, 2026; funded to end of 2028.","Phase 2 MOMENTUM enrollment on track for Q1 2027; ORR data expected H2 2027.","Roche DAC collaboration: $20M upfront paid May 2026; new Phase 1b trial with daratumumab/carfilzomib to start H1 2027.","EHA 2026 data: ORR 40% at 75 µg and 53% at 100 µg doses in late-line MM; 2 MRD-negative patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-055490","json":"https://secwatch.observer/filing/0001628280-26-055490.json","markdown":"https://secwatch.observer/filing/0001628280-26-055490.md","text":"https://secwatch.observer/filing/0001628280-26-055490.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828026055490/0001628280-26-055490-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828026055490/cccc-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:15:13.007304+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}